DaVita (NYSE:DVA) Reaches New 12-Month High – What’s Next?

Shares of DaVita Inc. (NYSE:DVA) reached a new 52-week high during trading on Wednesday . The company traded as high as $211.95 and last traded at $208.9090, with a volume of 765773 shares traded. The stock had previously closed at $209.75.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. TD Cowen boosted their price target on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and boosted their price target for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. UBS Group boosted their price target on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Truist Financial boosted their price target on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus target price of $199.17.

DaVita Stock Performance

The company’s 50 day moving average price is $178.66 and its 200-day moving average price is $147.52. The company has a market cap of $13.41 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 0.69 and a beta of 0.91.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business’s revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts forecast that DaVita Inc. will post 15.07 earnings per share for the current year.

Insider Activity

In other news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Cozad Asset Management Inc. purchased a new position in shares of DaVita in the first quarter worth approximately $212,000. Western Wealth Management LLC purchased a new position in shares of DaVita in the first quarter worth approximately $60,000. Edgestream Partners L.P. purchased a new position in shares of DaVita in the first quarter worth approximately $398,000. Kentucky Retirement Systems purchased a new position in shares of DaVita in the first quarter worth approximately $2,240,000. Finally, Janus Henderson Group PLC increased its position in shares of DaVita by 96.2% in the first quarter. Janus Henderson Group PLC now owns 37,188 shares of the company’s stock worth $5,716,000 after acquiring an additional 18,237 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.